Currently out of the existing stock ratings of Andreas Argyrides, 76 are a BUY (76%), 19 are a HOLD (19%), 5 are a SELL (5%).

Andreas Argyrides

Work Performance Price Targets & Ratings Chart

Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 30.89% that have a potential upside of 42.9% achieved within 144 days. Previously, Andreas Argyrides worked at WEDBUSH.

Andreas Argyrides’s has documented 198 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KALA, Kala Pharmaceuticals at 02-Jun-2025.

Wall Street Analyst Andreas Argyrides

Analyst best performing recommendations are on RGNX (REGENXBIO).
The best stock recommendation documented was for RGNX (REGENXBIO) at 2/28/2024. The price target of $21 was fulfilled within 2 days with a profit of $1.1 (5.53%) receiving and performance score of 27.64.

Average potential price target upside

of $45.54 (40.4%) on ASND (ASCENDIS PHARMA AS).
of $18.63 (19.37%) on BMRN (BIOMARIN PHARMACEUTICAL).
of $14.29 (117.89%) on VRNA (VERONA PHARMA PLC ADR).

RGNX Regenxbio UBX Unity Biotechnology ALBO Albireo Pharma ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical AQST Aquestive Therapeutics SGMO Sangamo Therapeutics AVTE Aerovate Therapeutics KALA Kala Pharmaceuticals UTHR United Therapeutics VRNA Verona Pharma PLC ADR GBT Global Blood Therapeutics GOSS Gossamer Bio IMUX Immunic KROS Keros Therapeutics LQDA Liquidia Technologies MLTX MoonLake Immunotherapeutics RANI Rani Therapeutics Holdings PCRX Pacira Pharmaceuticals SRPT Sarepta Therapeutics CLSD Clearside Biomedical OCS Oculis Holding AG Ordinary shares SPRY ARS Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Daniil Gataulin (CHARDAN CAPITAL)